The number India doesn't have
Ask how many autistic people live in India and there is no answer. Not a contested answer, no answer. The country runs no routine autism count, so every national figure traces back to studies, not a system. The strongest of them, a 2018 door-to-door study of 3,964 children across five regions, put prevalence near 1%. The United States, which actually monitors, reports 1 in 31. That gap is not biology. It is measurement. And the missing number is not a footnote to the policy problem. It is the policy problem.
01 — Not rarer, just unseen
India doesn't have less autism. It sees less of it.
The instinct is to read India's 1% against America's 1-in-31 and conclude autism is simply less common here. The evidence says otherwise. Reported prevalence has climbed over time mainly through better case-finding and community sampling, not any measured rise in how often autism occurs. Census 2011 recorded disability at barely 1.1% in ages 0 to 4, roughly ten times lower than systematic developmental assessment later found in the same age group. When you look properly, you find more. When you don't look, the number stays comfortably, and misleadingly, small.
02 — The lost window
Concerns surface early. Diagnosis arrives years late.
Autism can be reliably identified by 18 to 24 months, and parents often notice differences between 6 and 18 months. In India, diagnosis typically lands at four to five years, and about 40% of families see several clinicians before anyone names it. The years in between are precisely the window when early intervention does the most good, and India spends them on "wait and watch," fragmented referrals and non-specific labels. You cannot shorten a delay you do not measure, and India measures this only in one-off studies, never as routine.
03 — The wrong shape of money
Autism needs recurring support. India funds hospital episodes.
Autism is a lifelong, outpatient, therapy-heavy condition: speech, occupational and behavioural support, year after year. India's financing is built for the opposite shape. The National Trust's Niramaya scheme caps cover at ₹1 lakh, and Ayushman Bharat is designed around ₹5 lakh hospitalisation episodes, not recurring therapy. This matters more because autism rarely travels alone: in the 2018 study, 79.6% of autistic children had at least one other neurodevelopmental condition. A single low cap and a hospitalisation-first design miss the real cost shape of autism care almost entirely.
04 — The pipeline, not just the posting
You cannot deploy specialists a pipeline is not producing
Even where the will exists, the workforce isn't there. India has roughly 28,535 special educators against about 22.5 lakh children with special needs, and around 1.5 lakh sanctioned posts sit vacant. Only a handful of institutions run autism-specific degree programmes. This is the same pattern as last week's rural specialists: the constraint is not a recruitment drive, it is a supply line that was never built. And, once again, no routine data tracks the vacancy or the training throughput as it moves.
Notice the through-line. Prevalence, diagnosis age, financing fit, workforce, every one of these failures is invisible because nothing routinely measures it. Recognition in India is strong; the law, the schemes and the awareness all exist. Monitoring is what's missing.
05 — So what
Fix the measurement first, because everything else depends on it
For policy: build the count before the next scheme
A routine autism surveillance function, age at diagnosis, waiting times, service coverage, adult cohorts, is the cheapest high-leverage move available. Every downstream fix, financing, workforce, schools, is currently flying blind because the numbers refresh only when a researcher runs a one-off study.
For insurers and financing: match the cost shape, not the hospital
The need is recurring outpatient therapy for a co-occurring cluster of conditions. A ₹1 lakh cap and a hospitalisation design are the wrong instrument. The opportunity is a recurring-therapy benefit, and the data to price it will only exist once someone measures it.
For digital health: screening and the missing registry are the same gap
Early screening tools, developmental checks at the first point of contact, and a real longitudinal registry are the arbitrage. Whoever helps India routinely see autism, from first screen to certification to school outcome, is building the layer every other intervention needs.
Explore the full dossier. The companion data tool holds the complete picture, prevalence by method, the diagnosis pathway, state-by-state early-intervention capacity, financing, workforce, the global comparison, a city directory and full sources. Open the autism data dashboard →
India built the recognition, the rights law, the schemes, the awareness. What it never built is the habit of counting. Until autism is something the system routinely measures rather than something researchers occasionally estimate, every other fix is aimed at a target nobody can see.